Concepedia

Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine Tumors

Jeanne Kowalski

Molecular Imaging and Biology · 2003 · 304 citations · 10 references

DOI

Concepts

References

10

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

Christian Waldherr, Miklos Pless, Helmut R. Maëcke et al. · PubMed · 2002 · 446 citations

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study

Christian Waldherr, Misha Pless, Helmut R. Maëcke et al. · Annals of Oncology · 2001 · 394 citations

, , +7

Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours

Stefan Adams, Richard P. Baum, Thomas Rink et al. · European Journal of Nuclear Medicine and Molecular Imaging · 1997 · 388 citations

, , +10

Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy

A. Heppeler, Sylvie Froidevaux, Helmut R. Mäcke et al. · Chemistry - A European Journal · 1999 · 332 citations

, , +18

64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.

Carolyn J. Anderson, Farrokh Dehdashti, Paul Cutler et al. · PubMed · 2001 · 275 citations